About: Celebrex adjuvant therapy on COVID-19: An experimental study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Celebrex adjuvant therapy on COVID-19: An experimental study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Celebrex adjuvant therapy on COVID-19: An experimental study
Creator	Wang, Jian Hong, Wenxin Zhang, Fuchun Chen, Yan Chen, Tingting Chen, Xinwen Yang, Zhen Yuan, Fang Chen, Xudan Peng, Ping Li, Yinxiong Tai, Qiang Tan, Shenglin Tao, Jiawang Wu, Feima Xiong, Yue You, Kai Zhang, Jiaye
Source	MedRxiv
abstract	Background: The world is under serious threat with the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19). However, there is no effective drug for the treatment of COVID-19. Based on analyses of available data, we deduced that the excessive prostaglandins E2 (PGE2) accumulation mediated by cyclooxygenase-2 (COX-2) was the key pathological basis of COVID-19. Methods: The urine PGE2 levels were measured by mass spectrometry. An experimental study about Celebrex to treat COVID-19 was conducted based on routine treatment. A total of 44 confirmed COVID-19 patients were enrolled (Experimental group n=37, Control group n=7). Patients in experimental group were given Celebrex once or twice a day (0.2 g/time) for 7-14 days. The dosage or duration was modified for individuals. Clinical outcomes of Celebrex adjuvant therapy were evaluated by vital signs, laboratory tests, and computed tomography upon the discontinuance of Celebrex. Results: We found that the concentrations of PGE2 in urine samples of COVID-19 patients were significantly higher than that of healthy individuals (mean value is 170 ng/ml vs 18.8 ng/ml, p<0.01) and positively correlated with the progression of COVID-19. Among the experimental group (ordinary n=29, severe n=7, critical n=1), 25 cases were treated with full dose and 11 cases with half dose of Celebrex, and 1 case with Ibuprofen. The remission rate were 100%, 82% and 57% in full dose, half dose and control group respectively. Celebrex significantly reduced the PGE2 levels and promoted recovery of ordinary or severe COVID-19. Conclusion: Our study suggests that Celebrex adjuvant treatment may be helpful for the therapy of COVID-19.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1101/2020.05.05.20077610
has license	medrxiv
sha1sum (hex)	d1db277897fb7857651d61fe895790b8a450eac8
schema:url	https://doi.org/10.1101/2020.05.05.20077610
resource representing a document's title	Celebrex adjuvant therapy on COVID-19: An experimental study
resource representing a document's body	covid:d1db277897fb7857651d61fe895790b8a450eac8#body_text
is schema:about of	named entity 'COX-2' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'Celebrex' named entity 'hemodynamic' named entity 'clinical outcomes' named entity 'GraphPad Prism' named entity 'OVID' named entity 'critical stage' named entity 'peer review' named entity 'Celebrex' named entity 'oxygen exchange' named entity 'Th1' named entity 'lung' named entity 'COVID' named entity 'randomized, double-blind' named entity 'prostaglandins' named entity 'Th17' named entity 'COVID' named entity 'RT-PCR' named entity 'lipid' named entity 'Celebrex' named entity 'Celebrex' named entity 'antibiotics' named entity 'critical illness' named entity 'COVID-19' named entity 'prostaglandin' named entity 'epithelial cell' named entity 'Guangzhou' named entity 'missing data' named entity 'thromboxane A2' named entity 'correlation' named entity 'SARS-CoV' named entity 'infection' named entity 'protein' named entity 'fever' named entity 'SARS-CoV-2' named entity 'Celebrex' named entity 'Medical Ethics' named entity 'remission' named entity 'Celebrex' named entity 'medRxiv' named entity 'kidney' named entity 'prospective study' named entity 'supportive treatment' named entity 'SEM' named entity 'blood circulation' named entity 'clinical symptoms' named entity 'SARS-CoV' named entity 'Arterial partial pressure of oxygen' named entity 'clinical trial' named entity 'Fever' named entity 'pathology' named entity 'Prostaglandin' named entity 'SARS-CoV' named entity 'chest CT' named entity 'peer review' named entity 'dose-dependent manner' named entity 'nucleocapsid protein' named entity 'E20' named entity 'COX-2' named entity 'statistical analysis' named entity 'medRxiv' named entity 'Celebrex' named entity 'Celebrex' named entity 'E20' named entity 'secretion' named entity 'alveolar'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software